STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
Consumers also can purchase prescribed Wegovy through the company's NovoCare Pharmacy
doi:10.1016/j.jpedsurg.2008.02.068
Extra-Large Refreezable Gel Pack Included Keeps your GLP-1 medications cool for up to *30 hours, so your Mounjaro, Wegovy, or Ozempic pen stays within a safe temperature range during travel
Both treatments involve injections, so patients should ensure injection-site reactions have resolved and inform practitioners about all medications
Minor procedures like dental work or skin biopsies may not require a pause, but confirm with your surgical team and PlexusDx
